A Phase I/II Trial of Combined Chemotherapy with S-1 and Irinotecan in Patients with Recurrent Cervical Cancer.

A Phase I/II Trial of Combined Chemotherapy with S-1 and Irinotecan in Patients with Recurrent Cervical Cancer. - A Phase I/II Trial of Chemotherapy with S-1 and Irinotecan For Recurrent Cervical Cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016302

Enrollment

Registered

2015-01-22

Start date

2013-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Cervical Cancer

Interventions

A combination chemotherapy with S-1 and irinotecan.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Platinum-resistant recurrent cervical cancer

Exclusion criteria

Exclusion criteria: Platinum-sensitive recurrent cervical cancer

Design outcomes

Primary

Measure	Time frame
Maximum tolerated dose (MTD) Toxicities and Response Rate	—

Countries

Japan

Contacts

Public ContactSeiji Mabuchi

Osaka University Hospital Obstetrics and Gynecology

smabuchi@gyne.med.osaka-u.ac.jp06-6879-3351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026